Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zuzana Zděblová Čermáková has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    BLOOD DONOR MOTIVATION IN THE CONTEXT OF SOCIODEMOGRAPHIC CHARACTERISTICS AND MOTIVATIONAL FACTORS

    by Pavlína Rabasová, Karel Pavlica, Roman Pospíšil, Hana Konečná, Zuzana Čermáková

    Introduction: The motivation of donors to donate substances of human origin, such as blood and its components, bone marrow, gametes, and others, is influenced by various factors, such as sociodemographic characteristics, motivational factors, and the level of social competence. Aim: To describe and analyse the motivation of donors to donate blood and blood components in relation to sociodemographic characteristics and motivational factors at the Blood Centre of the University Hospital Ostrava. Design and Methods: Quantitative research based on an anonymous questionnaire survey, followed by inferential analysis of bivariate data. The self-designed questionnaire included 13 questions focusing on motivation to donate, donation experience, anonymity in donation, and sociodemographic data (gender, age, education, size of place of residence, monthly household income, and type of profession). Results: Six of the nine motivational factors were found to be statistically associated with sociodemographic characteristics. Age influenced attitudes towards commemorative medals (p=0,013). Gender was significant for four factors: the publication of donor lists (p=0,050), special health insurance (p=0,003), media coverage of donor and recipient stories (p=0,000), and more targeted information campaigns (p=0,013). Education was associated with declared donor preference in the event of an organ shortage (p=0,010) and with the publicity of donor lists (p=0,048). Household income was significant in relation to commemorative medals (p=0,000) and declared donor preference in cases of organ shortage (p=0,003). The results of our research supported the Technology Agency of the Czech Republic (TA CR) research study No. TL05000144, which formulated, for example, basic principles of compensation for donation in the Czech Republic and fundamental recommendations for recruitment campaigns targeting living body part donors. Conclusions: Motivating donors to donate human substances plays a key role in sustaining the health system and saving lives. Understanding individual donor characteristics and preferences is important for developing motivational strategies to encourage new and existing donors to donate. Our research findings contribute to the targeted sustainability of blood and blood component donation programmes.

  • Open Access

    HPV and RAD51 as Prognostic Factors for Survival in Inoperable Oral and Oropharyngeal Cancer in Patients Unfit for Chemotherapy Treated with Hyperfractionated Radiotherapy

    by Zuzana Zděblová Čermáková, Pavel Hurník, David Konvalinka, Jan Štembírek, Tereza Paračková, Kamila Resová, Jakub Cvek, Tomáš Blažek, Lukáš Knybel, Martin Formánek, et al.

    Introduction: The incidence of advanced oral cavity and oropharyngeal cancers is generally high. Treatment outcomes for patients, especially those unfit for comprehensive cancer treatment, are unsatisfactory. Therefore, the search for factors to predict response to treatment and increase overall survival is underway. Objective: This study aimed to analyze the presence of 32 HPV genotypes in tumor samples of 34 patients and the effect of HPV status and RAD51 on overall survival. Method: Tumor samples of 34 patients with locally advanced oropharyngeal or oral cavity cancer treated with accelerated radiotherapy in monotherapy were analyzed using reverse hybridization and immunohistochemistry for the presence of HPV and RAD51. Its effect on overall survival was examined. Results: Only two types of HPV were identified—HPV 16 (dominant) and HPV 66 (two samples). The HPV positivity was associated with a borderline insignificant improvement in 2-year (p = 0.083), 5-year (p = 0.159), and overall survival (p = 0.083). Similarly, the RAD51 overexpression was associated with borderline insignificant improvement in 2-year (p = 0.083) and 5-year (p = 0.159) survival. Conclusion: We found no statistically significant differences but detected trends toward improvement in the survival of HPV-positive and RAD51 overexpressing patients unfit for surgical treatment or chemotherapy treated with hyperfractionated radiotherapy. The trends, however, indicate that in a larger group of patients, the effects of these two parameters would likely be statistically significant.


  • Open Access

    Dose escalation in advanced floor of the mouth cancer: a pilot study using a combination of IMRT and stereotactic boost

    by Tomáš Blažek, Zuzana Zděblová Čermáková, Lukáš Knybel, Pavel Hurník, Jan Štembírek, Kamila Resová, Tereza Paračková, Martin Formánek, Jakub Cvek, Renata Soumarová

    Purpose: We evaluated the efficiency and toxicity of stereotactic hypofractionated boost in combination with conventionally fractionated radiotherapy in the treatment of advanced floor of the mouth cancer. Methods: Thirty-seven patients with advanced stage of the floor of the mouth cancer, histologically confirmed squamous cell carcinoma (p16 negative) ineligible for surgical treatment, were indicated for radiochemotherapy or hyperfractionated accelerated radiotherapy (HART). The radiotherapy protocol combined external beam radiotherapy (EBRT) and a stereotactic hypofractionated boost to the primary tumor. The dose delivered from EBRT was 70–72.5 Gy in 35/50 fractions. The hypofractionated boost followed with 10 Gy in two fractions. For the variables—tumor volume, stage and grade a multivariate analysis was performed to find the relationship between overall survival, local progression and metastasis. Toxicity was evaluated according to CTCAE scale version 4. Results: After a median follow-up of 16 months, 23 patients (62%) achieved complete remission. The median time to local progression and metastasis was 7 months. Local control (LC) at 2 and 5-years was 70% and 62%, respectively. Progression-free survival (PFS) and overall survival (OS) were 57% and 49% at 2 years and 41% and 27% at 5 years, respectively. Statistical analysis revealed that larger tumors had worse overall survival and a greater chance of metastasis. Log-Rank GTV > 44 ccm (HR = 1.96; [95% CI (0.87; 4.38)]; p = 0.11). No boost-related severe acute toxicity was observed. Late osteonecrosis was observed in 3 patients (8%). Conclusion: The combination of EBRT and stereotactic hypofractionated boost is safe and seems to be an effective option for dose escalation in patients with advanced floor of the mouth tumors who are ineligible for surgical treatment and require a non-invasive approach.